Precigen Q3 2023 loss per share $0.08; FDA agrees PRGN-2012 study pivotal for BLA

PRECIGEN, INC.

2023-Q3 EPS reported -$0.26

Cash and investments $79.0M as of Sep 30, 2023; cash runway projected into 2025.
Total revenues decreased 92% to $1.3M in Q3 2023 from $16.6M in Q3 2022, largely from prior-year non-cash collaboration revenue.
Loss from continuing operations $19.8M ($0.08 per share) vs. $7.6M ($0.04) in Q3 2022.
FDA agreed ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as pivotal for accelerated BLA; Phase 2 enrollment complete, expected completion Q2 2024.
SG&A costs down 9% in Q3 and 17% for first nine months 2023 vs. prior year, driven by reduced professional fees.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECIGEN, INC. reported financial results for third quarter 2023.

Period: third quarter 2023
Result: reported results

Exact text from the filing

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2023 financial results and progress of clinical programs.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-23-016146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.